B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

17.59 +0.02 (+0.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,898,153
Open 17.75
Bid (Size) 17.45 (2)
Ask (Size) 17.60 (3)
Prev. Close 17.57
Today's Range 17.23 - 17.79
52wk Range 3.060 - 17.87
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
From ADMA Biologics, Inc.
Via GlobeNewswire
Assessing ADMA Biologics: Insights From 4 Financial Analysts
Via Benzinga

Performance

YTD
+286.59%
+286.59%
1 Month
+31.37%
+31.37%
3 Month
+93.30%
+93.30%
6 Month
+230.02%
+230.02%
1 Year
+287.44%
+287.44%

More News

Read More
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
How Is The Market Feeling About ADMA Biologics?
Via Benzinga
Expert Ratings For ADMA Biologics
Via Benzinga
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
Via Investor's Business Daily
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
Via Benzinga
Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
3 Millionaire-Making Stock Picks With Astounding Growth Potential
Via InvestorPlace
Bull Run Alert: 3 Stocks Set to Soar in the Coming Months
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.